IN2014CN04187A - - Google Patents

Info

Publication number
IN2014CN04187A
IN2014CN04187A IN4187CHN2014A IN2014CN04187A IN 2014CN04187 A IN2014CN04187 A IN 2014CN04187A IN 4187CHN2014 A IN4187CHN2014 A IN 4187CHN2014A IN 2014CN04187 A IN2014CN04187 A IN 2014CN04187A
Authority
IN
India
Prior art keywords
toxin
recombinant
cdta
toxins
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Jon Henry Heinrichs
Jean Luc Bodmer
Susan Lynn Secore
Aaron Rudy Goerke
Aguilar Ivette Caro
Marie Pierre Gentile
Melanie S Horton
Matthew Ryan Miezeiewski
Julie M Skinner
Paulus Jacobus Antonius Sondermeijer
Shyamsundar Subramanian
Liefkens Karin Huberdina Antonia Van Der Heijden
Su Wang
Jinfu Xie
Rachel Flora Xoconostle
Julie K Zorman
Original Assignee
Merck Sharp & Dohme
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Intervet Int Bv filed Critical Merck Sharp & Dohme
Publication of IN2014CN04187A publication Critical patent/IN2014CN04187A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN4187CHN2014 2012-01-27 2013-01-25 IN2014CN04187A (OSRAM)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US201261703754P 2012-09-20 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (1)

Publication Number Publication Date
IN2014CN04187A true IN2014CN04187A (OSRAM) 2015-07-17

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4187CHN2014 IN2014CN04187A (OSRAM) 2012-01-27 2013-01-25

Country Status (14)

Country Link
US (1) US9388394B2 (OSRAM)
EP (1) EP2807186A4 (OSRAM)
JP (2) JP2015506948A (OSRAM)
KR (1) KR20140117433A (OSRAM)
CN (1) CN104039816B (OSRAM)
AR (1) AR089797A1 (OSRAM)
AU (1) AU2013211973B2 (OSRAM)
BR (1) BR112014018432A8 (OSRAM)
CA (1) CA2856443A1 (OSRAM)
IN (1) IN2014CN04187A (OSRAM)
MX (1) MX351074B (OSRAM)
RU (1) RU2014134365A (OSRAM)
TW (1) TW201335178A (OSRAM)
WO (1) WO2013112867A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
CA2858519A1 (en) * 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
LT3160500T (lt) * 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2017014666A (es) 2015-05-15 2018-02-09 Sanofi Pasteur Inc Metodos de inmunización contra clostridium difficile.
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110088300A (zh) * 2016-12-14 2019-08-02 默沙东公司 与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
CA3056090A1 (en) * 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
BR112019024412A2 (pt) 2017-06-09 2020-07-14 Hipra Scientific, S.L.U. Usos de composição imunogênica e de vacina compreendendo toxóides de clostridium difficile para tratar e/ou prevenir doença causada por clostridium sp, composiçãoimunogênica e vacina compreendendo toxóides de c. difficile e c. perfringens, processo para preparar a dita vacina, bem como kit de vacinação que compreende a dita composição imunogênica
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
TW202035437A (zh) * 2018-10-17 2020-10-01 陳啟彰 預防艱難梭菌(clostridium difficile)感染的免疫原性組合物及方法
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP2023134918A (ja) * 2022-03-15 2023-09-28 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
AU2004304770B2 (en) 2003-12-08 2010-05-06 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP4588763B2 (ja) 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル(Clostridiumdifficile)毒素に対する抗体およびその使用
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2008012651A (es) * 2006-03-30 2009-03-06 Embrex Inc Procedimientos y composiciones para vacunacion de aves de corral.
DK2396652T3 (da) * 2009-02-11 2018-01-29 Cedars Sinai Medical Center Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
KR20120061053A (ko) * 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP2519257A4 (en) * 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
HUE033342T2 (en) 2010-09-03 2017-11-28 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai

Also Published As

Publication number Publication date
BR112014018432A2 (OSRAM) 2017-06-20
US20150044250A1 (en) 2015-02-12
AU2013211973A1 (en) 2014-06-12
RU2014134365A (ru) 2016-03-20
KR20140117433A (ko) 2014-10-07
MX351074B (es) 2017-09-28
AR089797A1 (es) 2014-09-17
JP2017141226A (ja) 2017-08-17
EP2807186A1 (en) 2014-12-03
CN104039816A (zh) 2014-09-10
MX2014009106A (es) 2014-11-10
CA2856443A1 (en) 2013-08-01
US9388394B2 (en) 2016-07-12
WO2013112867A1 (en) 2013-08-01
BR112014018432A8 (pt) 2017-07-11
CN104039816B (zh) 2018-02-09
EP2807186A4 (en) 2016-01-27
JP2015506948A (ja) 2015-03-05
TW201335178A (zh) 2013-09-01
AU2013211973B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
IN2014CN04187A (OSRAM)
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
MX373395B (es) Vacuna de haemophilus parasuis para serovar tipo cuatro.
EP4241851A3 (en) Immunogenic compositions
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
GB2515222A (en) Use of flagellin as a vaccine
WO2013084070A3 (en) Salmonella vaccine proteins
MX2015013808A (es) Vacuna contra garrapatas rhipicephalus.
MX2017014666A (es) Metodos de inmunización contra clostridium difficile.
WO2011084967A3 (en) Methods and compositions for providing protective immunity in the elderly
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
WO2020227605A3 (en) Dna encoded il-36 gamma as an adjuvant
MX2022001937A (es) Composicion inmunogenica.